CSL Ltd

CSL Ltd

CSL Limited develops, manufactures and markets human pharmaceutical and diagnostic products derived from human plasma. The Company's products include pediatric and adult vaccines, infection, pain medicine, skin disorder remedies, antivenoms, anticoagulants, and immunoglobulins.

Sector Health Technology Sub-Group Biotechnology
Total Shares 452.96 million Market Cap $57.55 billion
52 week high $143.33 52-week Low $92.10
1-Year Return 9.34% Relative Return (vsXJO) 5.32%
NTA $8.89 billion Price/NTA N/A
ROA 18.47% ROE 48.63%
Next Report N/A Next ex-div N/A
Index Member ASX 20, ASX 50, ASX 100, ASX 200, ASX 300, All Ords
Sector Health Technology
Sub-Group Biotechnology
Total Shares 452.96 million
Market Cap $57.55 billion
52 week high $143.33
52-week Low $92.10
1-Year Return 9.34%
Relative Return (vsXJO) 5.32%
NTA $8.89 billion
Price/NTA N/A
ROA 18.47%
ROE 48.63%
Next Report N/A
Next ex-div N/A
Index Member ASX 20, ASX 50, ASX 100, ASX 200, ASX 300, All Ords

Speak to a consultant about
CSL Ltd

ENQUIRE NOW

SEARCH FOR COMPANIES

Access our investment insights free

Not understanding the financials of even big blue chips can cost you precious income such as when Telstra reduced their dividends.
This is why our hugely popular Income report has become a must read report for all income investors

Download the Income Report for free to get the top ASX Dividend Stock Recommendations for 2018.

Download Now

We’re here to help

Need to speak to someone about companies or investing?
Our knowledgeable team is on hand to assist